2. Signaling Pathways
  3. Neuronal Signaling
    Stem Cell/Wnt
  4. Notch

Notch

Notch

Related Products

PDF 0.58 MB

Notch signaling is evolutionarily conserved and operates in many cell types and at various stages during development. Notch signaling occurs via cell-cell communication, where transmembrane ligands on one cell activate transmembrane receptors on a juxtaposed cell.

Regulation of Notch signaling is critical to development and maintenance of most eukaryotic organisms. The Notch receptors (NOTCH1, 2, 3, and 4) and ligands (DLL1, 3, and 4, JAG1 and 2) are integral membrane proteins and direct cell-cell interactions are needed to activate signaling. Ligand-expressing cells activate Notch signaling through an unusual mechanism involving Notch proteolysis to release the intracellular domain from the membrane, allowing the Notch receptor to function directly as the downstream signal transducer.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P1985A
    Notch 1 TFA
    Notch 1 TFA (Notch homolog 1, translocation-associated) can encode a member of the NOTCH family of proteins. Members of this Type I transmembrane protein family share structural characteristics including an extracellular domain consisting of multiple epidermal growth factor-like (EGF) repeats, and an intracellular domain consisting of multiple different domain types.
    Notch 1 TFA
  • HY-10585AS1
    Valproic acid-d14 sodium
    		Activator
    Valproic acid-d14 (sodium) is deuterium labeled Valproic acid (sodium). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.
    Valproic acid-d<sub>14</sub> sodium
  • HY-104031
    tCFA15
    		Modulator 99.37%
    tCFA15 is a trimethyl cyclohexenonic long chain fatty alcohol containing 15 carbon atoms on the side chain, promotes the differentiation of neurons, and may regulates Notch signaling.
    tCFA15
  • HY-124484
    JI130
    		Inhibitor 99.01%
    JI130 (JI051 derivative?) is a stabilizer for the?Hes1-PHB2?interaction. JI130 inhibits?the ability of Hes1 to repress transcription. JI130?significantly reduces the tumor growth in a murine pancreatic tumor model and has the potential for ?managing pancreatic cancer.
    JI130
  • HY-N10790
    RA-V
    		99.58%
    RA-V is a cyclic hexapeptide. RA-V has activity against Wnt, Myc and Notch with IC50 values of 50, 75, and 93 ng/mL, respectively. RA-V can be used for the research of cancer-related signaling pathways.
    RA-V
  • HY-P99377
    Navicixizumab
    		Inhibitor
    Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel (HY-B0015) for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer.
    Navicixizumab
  • HY-13526G
    YO-01027 (GMP)
    		Inhibitor
    YO-01027 (Dibenzazepine) (GMP) is YO-01027 (HY-13526) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. YO-01027 is a potent γ-secretase inhibitor.
    YO-01027 (GMP)
  • HY-10585AS
    Valproic acid-d7 sodium
    		Activator
    Valproic acid-d7 (sodium) is the deuterium labeled Valproic acid (sodium salt). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].
    Valproic acid-d<sub>7</sub> sodium
  • HY-10585S
    Valproic acid-d4
    		Activator ≥98.0%
    Valproic acid-d4 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].
    Valproic acid-d<sub>4</sub>
  • HY-P1846
    Jagged-1 (188-204)
    		Agonist
    Jagged-1 (188-204) is a fragment of the Jagged-1 (JAG-1) protein with Notch agonist activity. JAG-1 is a Notch ligand highly expressed in cultured and primary multiple myeloma (MM) cells. JAG-1 induces maturation of monocyte-derived human dendritic cells.
    Jagged-1 (188-204)
  • HY-10585S4
    Valproic acid-d4-1
    		Activator
    Valproic acid-d4-1 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].
    Valproic acid-d<sub>4</sub>-1
  • HY-10585B
    Valproic acid (sodium)(2:1)
    		Activator
    Valproic acid (VPA) sodium (2:1) is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium (2:1) activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium (2:1) is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches.
    Valproic acid (sodium)(2:1)
  • HY-145428
    BT-GSI
    		Inhibitor
    BT-GSI is a γ-secretase inhibitor (GSI) and a bone-targeted Notch inhibitor. BT-GSI has dual anti-myeloma and anti-resorptive properties, which can be used for the research of multiple myeloma and associated bone disease. BT-GSI inhibits tumor growth and osteolytic disease progression.
    BT-GSI
  • HY-P99925
    Enoticumab
    		Inhibitor
    Enoticumab (REGN421, SAR153192) is an IgG1κ antibody targeting human Dll4. DLL4 is a ligand of the Notch signaling pathway and regulates fatty acid uptake through non-transcriptional regulation of macropinocytosis-dependent long-chain fatty acid uptake. Specific in vivo activity of Enoticumab in an ovarian xenograft model. EGN421 (2.5 mg/kg once weekly) resulted in 86% and 83% tumor growth inhibition in mouse subcutaneous TOV-112D or intraperitoneal A2780 human tumor xenograft models, respectively.
    Enoticumab
  • HY-10585S2
    Valproic acid-d15
    		Activator ≥99.0%
    Valproic acid-d15 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].
    Valproic acid-d<sub>15</sub>
  • HY-N9790
    Procyanidin B2 3,3'-di-O-gallate
    		Inhibitor
    Procyanidin B2, 3,3'-di-O-gallate is an active constituent. Procyanidin B2, 3,3'-di-O-gallate can be isolated from grape seed extract (GSE) procyanidin mix. Procyanidin B2, 3,3' -di-o-gallate target cancer stem cells (CSCs) in prostate cancer (PCa). Procyanidin B2, 3,3'-di-O-gallate targets both unsorted and sorted CSCs at lower doses. Procyanidin B2, 3,3'-di-O-gallate strongly suppresses the constitutive as well as Jagged1 (Notch1 ligand)-induced activated Notch1 pathway.
    Procyanidin B2 3,3'-di-O-gallate
  • HY-P2203A
    SAHM1 TFA
    		Inhibitor
    SAHM1 TFA is a Notch pathway inhibitor. SAHM1 TFA stabilizes hydrocarbon-stapled alpha helical peptide. SAHM1 TFA targets the protein-protein interface and prevents Notch complex assembly.
    SAHM1 TFA
  • HY-E70292
    N-Acetylgalactosaminyltransferase 11
    		Activator
    N-Acetylgalactosaminyltransferase 11 (GALNT11) is a glycosylation transferase capable of activating the Notch signal.
    N-Acetylgalactosaminyltransferase 11
  • HY-10585S3
    Valproic acid-d4 sodium
    		Activator
    Valproic acid-d4 (sodium) is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.
    Valproic acid-d<sub>4</sub> sodium
  • HY-E70172
    Heparan Sulfate 3-O-Sulfotransferase 4
    		Modulator
    Heparan Sulfate 3-O-Sulfotransferase 4 is a sulfotransferase. Heparan Sulfate 3-O-Sulfotransferase 4 regulates Notch signaling.
    Heparan Sulfate 3-O-Sulfotransferase 4
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity